S34-1040
S34-1040 is an AKR1C3 inhibitor with a human IC50 of 0.03 μM and exhibits no detectable inhibition of AKR1C1, AKR1C2, or AKR1C4. S34-1040 functions as a chemosensitizer and restores sensitivity of doxorubicin-resistant breast cancer cells to doxorubicin. S34-1040 can be used for the research of doxorubicin-resistant breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3099381-90-2
- 화학식: C18H17N3O2
- 분자량:307.35
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
All 17β-HSD Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
AKR1C3 0.03 μM (IC50) |
In Vitro
S34-1040 potently and selectively inhibits recombinant AKR1C3 with an IC50 of 0.03 μM, and exhibits over 2500-fold selectivity over the structurally related AKR1C1, AKR1C2 and AKR1C4 isoforms[1].
S34-1040 (0-100 μM; 72-96 h) alone does not inhibit the proliferation of MCF-7/DOX cells even at a concentration as high as 100 μM. However, when treated with a protocol of 10-50 μM pre-incubation for 24 h followed by combined treatment for 72 h, it exerts strong synergistic effects with Doxorubicin (HY-15142A) to restore chemosensitivity, with a combination index (CI) ranging from 0.176 to 0.562[1].
Combined treatment with S34-1040 (10 μM; 14 days) and Doxorubicin completely inhibits long-term colony formation of MCF-7/DOX cells, whereas S34-1040 alone has no effect on clonogenic growth[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:doxorubicin-resistant MCF-7/DOX breast cancer cells
-
Concentration:0, 5, 10, 25, 40, 60, 80, 100 μM (single-agent); 0, 10, 25, 50 μM μM (combination with 0, 10, 25, 50 μM Doxorubicin)
-
Incubation Time:72-96 h (single-agent); 24 h pre-incubation, followed by 72 h co-treatment (combination)
-
Result:Showed weak antiproliferative activity even at concentrations up to 100 μM, with good cellular safety as a single agent.
Produced significantly stronger antiproliferative effects than Doxorubicin alone across all tested concentrations when combined with Doxorubicin.
Demonstrated strong to very strong synergy between S34-1040 and doxorubicin, with combination index (CI) values ranging from 0.176 to 0.562.
-
Cell Line:doxorubicin-resistant MCF-7/DOX breast cancer cells
-
Concentration:10 μM (single-agent); 10 μM combined with 25 μM Doxorubicin
-
Incubation Time:14 days
-
Result:Significantly suppressed the colony-forming ability of MCF-7/DOX cells, with no visible colonies remaining when combined with Doxorubicin.
Showed no significant difference compared to the blank control when used alone.
Saw doxorubicin alone at 25 μM fail to completely inhibit colony formation.
Chemical Information
-
CAS No. 3099381-90-2
-
분자량 307.35
-
화학식 C18H17N3O2
-
SMILES
N#CC1=CC=C(C=C1)CN(C)C(C2=CC(C(C3CC3)=O)=CN2)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
S34-1040 Related Classifications
HY-184928 Related Classifications
Powered by Bioz